Kyverna Therapeutics Raises $60M Series B Extension; Series B to $145M
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
FinancialContent fully hosted finance channel
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
ReNAgade Therapeutics and other early stage startups are raking in cash as science is moving at a pace that’s “unprecedented.”
Volastra Therapeutics has concluded the in-licensing of Amgen’s oral, first-in-class small molecule KIF18A inhibitor, sovilnesib (AMG650).